Clinical study of Bozi glycopeptide joint ascites reinfusion in the treatment cirrhosis conbined with pontaneous bacterial peritonitis
10.13699/j.cnki.1001-6821.2015.20.005
- VernacularTitle:薄芝糖肽联合腹水浓缩回输对肝硬化合并自发性细菌性腹膜炎的临床研究
- Author:
Peng MA
1
;
Yong-Gang YAO
;
Ming XIE
;
Shao-Jun DAI
;
Chuan-Xin ZOU
;
Xiong-Shan SHEN
Author Information
1. 华中科技大学同济医学院 附属荆州医院 消化内科
- Keywords:
Bozhi glycopeptide;
angina pectoris ascites reinfusion;
cirrhosis;
bacterial peritonitis
- From:
The Chinese Journal of Clinical Pharmacology
2015;(20):1999-2001
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigated the effect and safety of Bozi glyco-peptide joint ascites reinfusion in the treatment cirrhosis conbined with pontaneous bacterial peritonitis.Methods A total of 56 cases of cirrhotic patients with spontaneous bacterial peritonitis were selected and divided into two groups.The control group (28 cases) were treated with ascites reinfusion while experiment group ( 28 cases ) were treated with Bozhi glycopeptide 4 mL joint ascites reinfusion for two weeks.Lipopolysaccha-ride -binding protein, tumor necrosis factor -αand procalcitonin levels, liver function, complications were observed before and after treat-ment.Results Lipopolysaccharide -binding protein, tumor necrosis factor -αand procalcitonin levels of two groups patients all obviously re-duced ( P <0.05 ) , and those of experiment group were significantly lower than the control group ( P<0.05).Alanine aminotransferase levels of two groups obviously reduced with albumin levels increased ( P<0.05) , and alanine aminotransferase of the experiment group was significantly lower than that of control group, the albumin level was higher ( P <0.05 ) . Total effective rate of the experiment group ( 82.14%) were significantly higher than that of control group (53.57%) (P<0.05).The complication rate of the experiment group (7.14%) were significantly lower than that of control group (32.14%) (P<0.05).Conclusion Bozhi glycopeptide joint ascites reinfusion can effectively treat cirrhosis combined with spontaneous bacterial peritonitis and improve clinical symptoms that can not only improve treat-ment but also be safe.
